Zentalis Pharmaceuticals (ZNTL) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$0.37.
- Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) rose 3392.86% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.07, marking a year-over-year increase of 1686.75%. This contributed to the annual value of -$2.33 for FY2024, which is 4779.58% up from last year.
- As of Q3 2025, Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.37, which was up 3392.86% from -$0.37 recorded in Q2 2025.
- In the past 5 years, Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of $0.14 during Q1 2024, and its lowest value of -$1.85 during Q2 2023.
- For the 4-year period, Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around -$0.85, with its median value being -$0.83 (2023).
- Per our database at Business Quant, Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) surged by 11308.41% in 2024 and then crashed by 57857.14% in 2025.
- Quarter analysis of 4 years shows Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.92 in 2022, then increased by 9.78% to -$0.83 in 2023, then grew by 19.53% to -$0.67 in 2024, then skyrocketed by 44.6% to -$0.37 in 2025.
- Its last three reported values are -$0.37 in Q3 2025, -$0.37 for Q2 2025, and -$0.67 during Q1 2025.